Department of Surgical Pathology, Hyogo Medical University School of Medicine, Nishinomiya, Japan.
Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Int J Clin Oncol. 2024 Jun;29(6):647-680. doi: 10.1007/s10147-024-02488-1. Epub 2024 Apr 13.
The Japan Society of Clinical Oncology Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) have been published in accordance with the Minds Manual for Guideline Development 2014 and 2017. A specialized team independent of the working group for the revision performed a systematic review. Since GIST is a rare type of tumor, clinical evidence is not sufficient to answer several clinical and background questions. Thus, in these guidelines, we considered that consensus among the experts who manage GIST, the balance between benefits and harms, patients' wishes, medical economic perspective, etc. are important considerations in addition to the evidence. Although guidelines for the treatment of GIST have also been published by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), there are some differences between the treatments proposed in those guidelines and the treatments in the present guidelines because of the differences in health insurance systems among countries.
《日本临床肿瘤学会 2022 年胃肠间质瘤临床实践指南》是根据 2014 年和 2017 年《指南制定思维手册》制定的。一个独立于工作组的专门团队对该指南进行了系统评价。由于胃肠间质瘤是一种罕见的肿瘤，临床证据不足以回答几个临床和背景问题。因此，在这些指南中，我们认为管理胃肠间质瘤的专家之间的共识、获益与风险的平衡、患者的意愿、医疗经济角度等，除了证据之外，也是重要的考虑因素。虽然国家综合癌症网络（NCCN）和欧洲肿瘤内科学会（ESMO）也发布了胃肠间质瘤治疗指南，但由于各国医疗保险制度的差异，这些指南中提出的治疗方法与本指南中的治疗方法存在一些差异。
